known hypersensitivity to any component of the study medication(s). signs of multisystem organ failure. liver function tests (lfts) > 5x normal. intubated > 72 continuous hours. assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol. pregnant and nursing women. a negative serum pregnancy test during screening (within 72 hours prior to the first dose) must be documented before mscs are administered to a female subject of child-bearing potential.

known hypersensitivity to any component of the study medication(s). signs of multisystem organ failure. liver function tests (lfts) > 5x normal. intubated > 72 continuous hours. assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol. pregnant and nursing women. a negative serum pregnancy test during screening (within 72 hours prior to the first dose) must be documented before mscs are administered to a female subject of child-bearing potential.

1. known hypersensitivity to any component of the study medication(s). 2. signs of multisystem organ failure. liver function tests (lfts) > 5x normal. 3. intubated > 72 continuous hours. 4. assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol. 5. pregnant and nursing women. a negative serum pregnancy test during screening (within 72 hours prior to the first dose) must be documented before mscs are administered to a female subject of child-bearing potential.

1. known hypersensitivity to any component of the study medication(s). 2. signs of multisystem organ failure. liver function tests (lfts) > 5x normal. 3. intubated > 72 continuous hours. 4. assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol. 5. pregnant and nursing women. a negative serum pregnancy test during screening (within 72 hours prior to the first dose) must be documented before mscs are administered to a female subject of child-bearing potential.